1. BMY's Q2 results exceeded expectations, largely driven by strong sales of Eliquis and Opdivo. 2. The solid performance of Revlimid also contributed to BMY's strong financials this quarter.
The significant beat on Q2 estimates signals robust demand for key products. Historical performance post-earnings beats often leads to stock price increases, as seen with other biotech firms.
The article highlights better-than-expected earnings which can significantly attract investor interest and improve market sentiment toward BMY.
Positive earnings reports typically boost stock prices in the immediate aftermath, though sustained performance depends on ongoing product demand.